(Q36807468)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

review article

1 reference

title

Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

Sébastien Lacroix-Desmazes

30 December 2019

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

3

Michel D Kazatchkine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

4

Srini V Kaveri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

1 reference

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Rheumatology

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

262-272

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

Complications of intravenous immune globulin treatment in neurologic disease

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Humanised monoclonal antibody therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

T-cell-targeted therapies in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Cytokine profiles during infliximab monotherapy in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

TNF downmodulates the function of human CD4+CD25hi T-regulatory cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

BLyS and APRIL in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Cytokine networks--towards new therapies for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Intravenous immunoglobulin in autoimmune neuromuscular diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Intravenous immunoglobulin therapy of antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. IV immunoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Mechanisms of disease: atherosclerosis in autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-? present in serum from patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Partitioning of TSE infectivity during ethanol fractionation of human plasma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0481

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0481

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17471245%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference